The Authors' Reply to "Efficacy and Feasibility of Edoxaban Therapy without Prior Parenteral Anticoagulants in Patients with Venous Thromboembolism".
作者信息
Ueno Yuki, Ikeda Satoshi, Motokawa Tetsufumi, Honda Tomohiro, Kurobe Masaya, Akashi Ryohei, Yonekura Tsuyoshi, Yoshimuta Tsuyoshi, Eguchi Masamichi, Kawano Hiroaki, Maemura Koji
机构信息
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
出版信息
Intern Med. 2024 Nov 1;63(21):3015-3016. doi: 10.2169/internalmedicine.3509-24. Epub 2024 Mar 4.
Abstract
摘要
相似文献
1
The Authors' Reply to "Efficacy and Feasibility of Edoxaban Therapy without Prior Parenteral Anticoagulants in Patients with Venous Thromboembolism".
Intern Med. 2024 Nov 1;63(21):3015-3016. doi: 10.2169/internalmedicine.3509-24. Epub 2024 Mar 4.
2
Real-world Safety and Effectiveness of Edoxaban in Patients with Venous Thromboembolism with or without Preceding Parenteral Anticoagulants: A Single-center Retrospective Study.
Intern Med. 2024 Jul 1;63(13):1845-1853. doi: 10.2169/internalmedicine.2524-23. Epub 2023 Nov 20.
3
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Lancet Haematol. 2016 May;3(5):e228-36. doi: 10.1016/S2352-3026(16)00023-5. Epub 2016 Mar 22.
4
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Lancet Haematol. 2016 Aug;3(8):e379-87. doi: 10.1016/S2352-3026(16)30057-6. Epub 2016 Jul 1.
5
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.
6
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Lancet Haematol. 2016 Sep;3(9):e437-45. doi: 10.1016/S2352-3026(16)30080-1.
7
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Vasc Med. 2016 Aug;21(4):361-8. doi: 10.1177/1358863X16645853. Epub 2016 May 10.
8
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.
9
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28.
10
Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Thromb Res. 2015 Dec;136(6):1133-44. doi: 10.1016/j.thromres.2015.10.009. Epub 2015 Oct 20.
本文引用的文献
1
Real-world Safety and Effectiveness of Edoxaban in Patients with Venous Thromboembolism with or without Preceding Parenteral Anticoagulants: A Single-center Retrospective Study.
Intern Med. 2024 Jul 1;63(13):1845-1853. doi: 10.2169/internalmedicine.2524-23. Epub 2023 Nov 20.
2
Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
J Cardiol. 2018 Aug;72(2):120-127. doi: 10.1016/j.jjcc.2018.03.006. Epub 2018 Apr 13.
Zotero 插件